Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

#Lundbeck has said it won't raise its offer to buy #AvadelPharma any further, clearing the way for the sleep disorder specialist to complete a #merger with #Alkermes.

pharmaphorum.com/news/lundbec...

Alkermes offers more for Avadel after Lundbeck bid Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

#Alkermes has been forced to raise its offer for #narcolepsy drug developer #AvadelPharma, after a rival bid from #Lundbeck was deemed superior.

Lundbeck makes bid for Avadel, trying to displace Alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

Another pharma M&A fight has broken out, with #Lundbeck outbidding #Alkermes in an attempt to take control of #AvadelPharma and its approved therapy for the sleep disorder #narcolepsy.

Alkermes bets $2.1bn on Avadel and its narcolepsy drug Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.

#Alkermes has reached an agreement to buy #AvadelPharma in a deal valued at up to $2.1 billion, claiming rights to an FDA-approved therapy for sleep disorder #narcolepsy that has been predicted to make sales of up to $275 million this year.

pharmaphorum.com/news/alkerme...